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Abstract: Background 
This study aimed to quantify dispensed opioid prescriptions among primary 
care practices throughout England and investigate its association with 
socioeconomic status (SES). 
 
Methods 
This cross-sectional study used publicly available data in 2015, 
including practice-level dispensing data and characteristics of 
registrants from the United Kingdom (UK) National Health Service Digital, 
and Index of Multiple Deprivation (IMD) data from Department of 
Communities and Local Government. Practices in England which had opioid 
prescriptions that could be assigned a defined daily dose (DDD) in the 
claim-based dispensing database were included. The total amount of 
dispensed opioid prescriptions (DDD/1000 registrants/day) was calculated 
for each practice. The association between dispensed opioid prescriptions 
and IMD was analyzed by multi-level regression and adjusted for 
registrants' characteristics and the clustered effect of Clinical 
Commissioning Groups. Subgroup analysis was conducted for practices in 
London, Birmingham, Manchester and Newcastle. 
 
Results 
Of the 7856 included practices in England, the median and interquartile 
range (IQR) of prescription opioids dispensed was 36.9 (IQR: 23.1, 52.5) 
DDD/1000 registrants/day. The median opioid utilization (DDD/1000 
registrants/day) amongst practices varied between Manchester (53.1; IQR: 
36.8, 71.4), Newcastle (48.9; IQR: 38.8, 60.1), Birmingham (35.3; IQR: 
23.1, 49.4) and London (13.9; IQR: 8.1, 18.8). Lower SES, increased 
prevalence of patients aged more than 65 years, female gender, smoking, 
obesity and depression were significantly associated with increased 
dispensed opioid prescriptions. For every decrease in IMD decile (lower 
SES), there was a significant increase of opioid utilization by 1.0 (95% 
confidence interval: 0.89, 1.2, P<0.001) DDD/1000 registrants/day. 
 
Conclusion 
There was a variation in prescription opioids dispensed among practices 
from Northern and Eastern England to Southern England. A significant 
association between increased opioid prescriptions and greater 
deprivation at a population level was observed. Further longitudinal 
studies using individual patient data are needed to validate this 
association and identify the potential mechanisms.  
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Authors’ response to the Editors and/or Reviewers 
 
ASSOCIATE EDITOR COMMENTS: 
The authors have prepared a revised manuscript that addresses many of the methodologic 
limitations identified in the original submission. Although this analysis could make a 
contribution to the scientific literature on socioeconomic marginalization, the manuscript is 
still marred by many grammatical and spelling mistakes. Further revision is required to 
remove these errors and, more importantly, ensure the findings are accurately and succinctly 
expressed. To that end, I would re-emphasize the need for thorough copyediting. Particular 
attention should be paid to the Introduction and Discussion.  
 
[Reply] Revised as recommended.  
We have taken the reviewer and editor’s advice to revise sentences in the Introduction 
section and re-organize the structure of Discussion section. The revised manuscript has 
been scrutinized for any grammatical and spelling mistakes and proof-read by a senior 
researcher in the field who are native English speaker. The results of subgroup analyses 
were summarized, and detail information was moved to the supplementary material to make 
sure the main findings are succinctly presented.  
 
The authors should strongly consider reporting the subgroup analyses (e.g., lines 239 to 
285) in supplementary material to better focus the article.  
 
[Reply] Revised as recommended.  
We have taken the advice from the reviewer and editor to shorten the description of the 
subgroup analysis, and detail information, such as the association between the number of 
prescription opioids dispensed and registrants’ characteristics among the four primary urban 
areas has been moved to the supplementary material as the Appendix 1.  
 
Further, the authors should pay close attention to comments of the first reviewer about the 
Discussion, and the need to revise the writing to improve its readability. Currently, the 
Discussion is poorly structured with new paragraphs appearing haphazardly. I would suggest 
that the Discussion would improve substantially if shortened to adhere to a standard 
structure, e.g., a summary of the findings; followed by placing the findings in the context of 
previously-published literature; followed by implications for policy or practice; study 
limitations; and conclusion. 
 
[Reply] Revised as recommended.  
We have revised the Discussion section to improve the readability of the revised manuscript. 
The Discussion has been re-organized and structured into four sections with subheadings 
that signpost readers to the main findings, implications of scientific knowledge and clinical 
practice, and strengths and limitations.  
 
 
REVIEWER COMMENTS: 
Reviewer #1 
General comments: 
This is an improved manuscript. The authors have certainly made efforts to improve the 
methodology of their paper and it does provide granular data for an entire country, which is 
unique. Below are some general comments and minor comments. I have placed an asterix 
next to the comments that I consider major.  
 
Introduction 
1. *The readability of the manuscript remains low. Many of the sentences, particularly in the 
introduction (which should capture the reader's attention), are poorly constructed. For 
Response to Reviewers
example, line 29 "Although studies have found that higher deprivation (i.e. lower SES) 
was associated with higher opioid utilization according to the aggregate-level data of 
prescription opioids dispensed in the US (McDonald et al., 2012) and sales data of over-
the-counter and prescription opioids in Australia (Degenhardt et al., 2016), the 
generalizability of those finding to different counties is limited due to differing data 
sources and including different medicines." There are examples of this throughout the 
text. The messaging is lost. For this manuscript to make it to publication, there needs to 
be substantial copyediting. 
 
[Reply] Revised as recommended. 
We have rewritten some sentences and re-organized the Introduction section to 
summarize the published literature in order to highlight the knowledge gap. In addition, 
the revised manuscript has been scrutinized for any typographical and grammar 
mistakes. It has been proof-read by a pharmacoepidemiology researcher who is also a 
native English speaker. The revised sentences in the Introduction section are 
summarized as follows.  
 
[Page 6, line 7] 
“At a regional level, drug utilization studies in North America and Australia have also 
suggested there may be a link between regional opioid utilization, opioid-related harms 
and socioeconomic status.” 
 
[Page 7, line 29] 
“Socioeconomic status (SES) has been identified as a major determinant in the variation 
of regional opioid utilization as it is associated with chronic pain conditions, persistent 
opioid utilization and aberrant medication-taking behaviors.” 
 
 [Page 7, line 33] 
“Other factors are less important because opioids are classified as controlled substances 
which are restricted for use in pain management and strict regulations govern 
prescribing.” 
 
[Page 7, line 37] 
“Previous studies using aggregate-level data of prescription opioids dispensed in the US 
and sales data of over-the-counter and prescription opioids in Australia found that lower 
SES was associated with higher opioid utilization. However, the generalizability of these 
results is limited due to the measure of SES used.” 
 
[Page 8, line 49] 
“In the United Kingdom (UK), regional variation in health care provision has been 
identified in several diseases and regarded as an important health equity issue.” 
 
[Page 8, line 54] 
“…in Leeds and Bradford found that higher number of opioid prescribing was associated 
with lower SES …” 
 
2. Page 6, line 12: "States" should be changed to "states" 
 
[Reply] Revised as recommended. 
 
[Page 6, line 16] “…between states with the …” 
 
3. P8, line 49: The authors use the terms deprivation and SES interchangeably. Would use 
reference, as you have, that they are equivalent and then use only one term - probably 
SES. 
 
[Reply] Revised as recommended.  
We have changed the term ‘deprived’ to ‘low SES’, and those revised sentences are 
listed as follows.  
 
[Page 8, line 55] “…was associated with lower SES.” 
[Page 12, line 131] “It is often used to quantify SES and to inform the implementation …” 
[Page 12, line 136] “…with higher IMD score indicates a lower SES area.” 
[Page 13, line 138] “…indicates a lower SES area.” 
[Page 18, line 226] “…found that lower IMD decile (lower SES)” 
[Page 18, line 240] “…decile (lower SES), there was…” 
[Page 21, line 278] “…located in lower SES areas…” 
[Page 23, line 305] “…associated with lower SES which were …” 
[Page 24, line 329] “…lower neighborhood SES was related…” 
[Page 27, line 394] “…associated with lower SES when …” 
 
 
Methods 
1. The authors decided to analyze 1 year of data, likely because of data restrictions, time, 
etc. However, it may be difficult to draw definitive conclusions about opioid prescribing 
and SES from one year composite data. Ideally, the authors could look over multiple 
years to make their conclusions more generalizable. Was 2015 a representative year? 
Was there higher opioid prescribing among higher SES in previous years? 
 
[Reply] We applied the 2015 data because the UK SES data was only available in 2011 
and 2015. Moreover, the primary care practices in England were grouped into Clinical 
Commissioning Groups in 2012 for the commissioning of healthcare services in a local 
area (page 9, line 64-66). To inform the relevant issues related to current opioid 
prescribing, we decided that the most updated information (2015) should be used to 
identify the association between SES and prescription opioids dispensed. To clarify this 
reason, we add a sentence in the method section. Moreover, we also acknowledge the 
limitation due to data restriction and recommend that further studies with more data 
points are needed to validate the consistency of the association between SES and opioid 
prescribing. 
 
[Page 9, line 64] 
“The most up-to-date information on SES (in 2015) was linked with opioid utilization and 
other population characteristics data by the identifier at practice level.” 
 
[Page 26, line 377 to 382] 
“Moreover, due to data restriction and the implementation of CCGs in 2012, this study 
used only the most up-to-date information from one calendar year (2015). Ideally, further 
studies should acquire information from multiple years, including the upcoming calendar 
years, to validate the consistency of the association between SES and prescription 
opioids dispensed at the population level. “ 
 
2. Please include somewhere in the methods section the scale of IMD score (0 to XX) and 
whether a lower score represents lower SES or vice versa. In isolation, a median IMD 
score of 22.4 is meaningless. This is not mentioned until line 216 though I might have 
missed it elsewhere. 
 
[Reply] The explanation of the IMD score was included in the original manuscript (page 
12, line 126). To enhance this information, we revise the description as follows. 
 
[Page 12, line 135] 
“The IMD score ranges from 0 to 100, and a LSOA with higher IMD score indicates a 
lower SES area. In addition, each LSOA was ranked from the greatest to lowest IMD 
score, and the IMD rank was categorized into deciles. Therefore, a LSOA with lower IMD 
decile indicates a lower SES area.” 
 
3. Pg 10, line 83: "The number of female and registrants over 65 years in each practice 
were retrieved from NHS Digital"…unclear if this sentence is constructed properly 
"female and registrants". Please clarify. 
 
[Reply] Revised as recommended. 
 
[Page 10, line 91] 
“Within each practice, the number of female registrants and the number of registrants 
over 65 years were retrieved from NHS Digital.” 
 
[Page 14, line 156] 
“The proportion of female registrants and registrants aged over 65 years were calculated 
by dividing the number of female registrants and registrants aged over 65 years by the 
total number of registrants within each practice.” 
 
Results 
1. *Subgroup analysis of the 4 primary urban areas. I certainly understand the authors' 
need to demonstrate consistency, however, I will stress that the extensive discussion in 
the results detracts from the overall message of the paper. If the author's wish to 
demonstrate consistency, then I would summarize the findings of this section and put the 
remainder in the supplemental appendix. For example, "We performed a subgroup 
sensitivity analysis on 4 primary urban areas to demonstrate consistency of consistency 
of the association between SES and prescription opioids dispensed. The median opioid 
utilization varied XXX, XXX, XXX, XXX in Manchester, Newcastle, Birmingham, and 
London, respectively. In linear regression, we found a negative associated between IMD 
decile and opioid utilization in all four cities. There were inconsistent associations in 
these cities in other measures (Supplemental Appendix)." This way the main message of 
the paper is not lost, you ensure due diligence that you did additional analyses, and 
those persons from Newcastle can go to the appendix if they so choose to learn more 
about their city. 
 
[Reply] Revised as recommended.  
The results of subgroup analysis have been shortened, and the detail information 
regarding the inconsistent associations between opioids prescribing and registrants’ 
characteristics among the four primary urban areas have been moved to the 
supplementary material as Appendix 1. 
 
[Page 19, line 249 to 265] 
“In the four primary urban areas, the median opioid utilization varied…… was found 
between practices in the four cities (Table4) (Appendix 1).” 
 
 
Discussion 
1. Discussion. The discussion section needs further revision since the message is lost on 
the reader. The main finding of this paper is that there is an association between opioid 
use and SES. There are factors that certainly influence that (i.e., chronic pain is more 
common among those with lower SES), however, the message of the paper is diluted by 
the discussion. The author's should postulate why they think their findings are unique (no 
one has done this before, there were A LOT of opioid prescriptions, aggregated 
population data means better generalizability) and robust (validated composite tool to 
measure SES, models that were used are appropriate, etc), then discuss some 
implications to their findings and possible explanations of their findings (lack of training of 
healthcare providers, chronic pain, etc), then add a limitations section.  
 
[Reply] Revised as recommended 
We took the advice recommended by the editor and reviewer to restructure the 
Discussion into four sections with additional subheadings. We highlight the key message 
of each section as follows.  
 
[Page 21, line 267 to 285] This section highlights the main finding of this study. 
 
[Page 22, line 287 to 320] This section describes the implication of this study regarding 
how the study results contributing to the current scientific evidence. We found a 
consistent result in the association between SES and opioid prescribing when comparing 
with previous publications. 
 
[Page 24, line 322 to 352] This section indicates the implication of this study for clinical 
practices. We found there is a need for evidence-based guidance on opioid prescribing. 
 
[Page 25, line 354 to 368] This section outlines the strengths of this study. We 
emphasized the better generalizability related to the national data sources and the 
validity due to the official and standardized tool and analytical model. 
 
[Page 26, line 370 to 390] This section discusses the limitations of this study. The natural 
limitations of using aggregate level dispensing data have been mentioned. The influence 
of unmeasured characteristics on the association between SES and opioid prescribing 
was also explained.  
 
[Page 27, line 392 to 396] Conclusion – a summary of key messages. 
 
2. Page 25 line 351: "In this study, the amount of prescription opioids dispend", change 
word. 
 
[Reply] Revised as recommended 
 
[Page 24, line 324] 
“Therefore, the total amount of opioids dispensed in each region …” 
 
 
 
 
1 
Manuscript submitting to International Journal of Drug Policy 
Prescription opioids: regional variation and socioeconomic status – evidence 
from primary care in England  
 
Names of authors:  
Teng-Chou Chen a, Li-Chia Chen b, Miriam Kerry a, Roger David Knaggs a,c 
 
Names and address of affiliations:  
a. Division of Pharmacy Practice and Policy, School of Pharmacy, University of 
Nottingham, East Drive, University Park, Nottingham NG7 2RD, United Kingdom  
b. Centre for Pharmacoepidemiology and Drug Safety, Division of Pharmacy and 
Optometry, School of Health Sciences, Faculty of Biology, Medicine and Health, 
University of Manchester, Manchester Academic Health Science Centre Stopford 
Building, Oxford Road, Manchester M13 9PT, United Kingdom 
c. Pain Management Service and Pharmacy Department, Nottingham University 
Hospitals NHS Trust, Queen’s Medical Centre Campus, Derby Road, Nottingham 
NG7 2UH, United Kingdom 
 
Email address of authors:  
*Manuscript
Click here to view linked References
2 
Teng-Chou Chen: paxtc4@nottingham.ac.uk 
Li-Chia Chen: li-chia.chen@manchester.ac.uk 
Miriam Kerry: miriamkerry@gmail.com 
Roger Knaggs: roger.knaggs@nottingham.ac.uk 
 
Name of corresponding author: Roger David Knaggs 
Postal address: East Drive, University Park, Nottingham NG7 2RD, United Kingdom 
Telephone: +44(0)115 846 6382 
Fax: +44(0)115 846 6249 
Email address: roger.knaggs@nottingham.ac.uk 
 
Number of tables and figures: 4 tables and 2 figures and Figure 1 that color should 
be used in print  
3 
Prescription opioids: regional variation and socioeconomic status – evidence 
from primary care in England 
 
Keywords: Socioeconomic status; dispensed opioid prescriptions; regional variation; 
spatial analysis; general practice; England 
 
Abstract 
Background 
This study aimed to quantify dispensed opioid prescriptions among primary care 
practices throughout England and investigate its association with socioeconomic 
status (SES). 
Methods 
This cross-sectional study used publicly available data in 2015, including 
practice-level dispensing data and characteristics of registrants from the United 
Kingdom (UK) National Health Service Digital, and Index of Multiple Deprivation (IMD) 
data from Department of Communities and Local Government. Practices in England 
which had opioid prescriptions that could be assigned a defined daily dose (DDD) in 
the claim-based dispensing database were included. The total amount of dispensed 
opioid prescriptions (DDD/1000 registrants/day) was calculated for each practice. The 
4 
association between dispensed opioid prescriptions and IMD was analyzed by 
multi-level regression and adjusted for registrants’ characteristics and the clustered 
effect of Clinical Commissioning Groups. Subgroup analysis was conducted for 
practices in London, Birmingham, Manchester and Newcastle. 
Results 
Of the 7856 included practices in England, the median and interquartile range (IQR) 
of prescription opioids dispensed was 36.9 (IQR: 23.1, 52.5) DDD/1000 
registrants/day. The median opioid utilization (DDD/1000 registrants/day) amongst 
practices varied between Manchester (53.1; IQR: 36.8, 71.4), Newcastle (48.9; IQR: 
38.8, 60.1), Birmingham (35.3; IQR: 23.1, 49.4) and London (13.9; IQR: 8.1, 18.8). 
Lower SES, increased prevalence of patients aged more than 65 years, female 
gender, smoking, obesity and depression were significantly associated with increased 
dispensed opioid prescriptions. For every decrease in IMD decile (lower SES), there 
was a significant increase of opioid utilization by 1.0 (95% confidence interval: 0.89, 
1.2, P<0.001) DDD/1000 registrants/day. 
Conclusion 
There was a variation in prescription opioids dispensed among practices from 
Northern and Eastern England to Southern England. A significant association 
between increased opioid prescriptions and greater deprivation at a population level 
5 
was observed. Further longitudinal studies using individual patient data are needed to 
validate this association and identify the potential mechanisms.
6 
Introduction 1 
Opioids have been considered the standard care for managing acute severe pain and 2 
chronic pain (Rosenblum, Marsch, Joseph, & Portenoy, 2008). In the past decade, 3 
there has been a marked increase in opioid-related deaths in several developed 4 
countries that coincided with an increasing opioid utilization (Centers for Disease 5 
Control and Prevention, 2011; Gladstone, Smolina, & Morgan, 2016; Jauncey, Taylor, 6 
& Degenhardt, 2005). At a regional level, drug utilization studies in North America and 7 
Australia have also suggested there may be a link between regional opioid utilization, 8 
opioid-related harms and socioeconomic status (Degenhardt et al., 2016; Fischer, 9 
Jones, & Rehm, 2013a; Havens et al., 2007; McDonald, Carlson, & Izrael, 2012; 10 
Morden et al., 2014; Zerzan et al., 2006). 11 
 12 
Geographical variation in dispensed opioid prescriptions and over-the-counter opioids 13 
have been found in the United States (US) (McDonald et al., 2012; Morden et al., 14 
2014; Zerzan et al., 2006) and Australia (Degenhardt et al., 2016). In the US, there 15 
was a 7.3-times variation between states with the highest and lowest number of 16 
prescription opioids dispensed (McDonald et al., 2012). In Australia, according to 17 
sales data, major cities had lower levels of opioid utilization than remote areas, and 18 
there was a 2.5-fold difference between areas with the highest and lowest opioid 19 
7 
utilization in 2013 (Degenhardt et al., 2016). Furthermore, higher opioid-related 20 
morbidity and mortality have been observed in regions with higher opioid utilization in 21 
North America (Fischer, Jones, & Rehm, 2013b; Havens et al., 2007). 22 
 23 
A variety of factors may be attributed to the observed variation in opioid prescribing, 24 
such as population demographic characteristics (McDonald et al., 2012), prevalence 25 
of pain related co-morbidities (Painter, Crofford, & Talbert, 2013), healthcare provider 26 
clinical knowledge (Reames, Shubeck, & Birkmeyer, 2014), accessibility of 27 
appropriate services (McDonald et al., 2012), insurance coverage and benefit policy 28 
(Zerzan et al., 2006). Socioeconomic status (SES) has been identified as a major 29 
determinant in the variation of regional opioid utilization as it is associated with 30 
chronic pain conditions, persistent opioid utilization and aberrant medication-taking 31 
behaviors (Day, Conroy, Lowe, Page, & Dolan, 2006; Department of Health, 2012). 32 
Other factors are less important because opioids are classified as controlled 33 
substances which are restricted for use in pain management and strict regulations 34 
govern prescribing.  35 
 36 
Previous studies using aggregate-level data of prescription opioids dispensed in the 37 
US (McDonald et al., 2012) and sales data of over-the-counter and prescription 38 
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opioids in Australia (Degenhardt et al., 2016) found that lower SES was associated 39 
with higher opioid utilization. However, the generalizability of these results is limited 40 
due to the measure of SES used. Instead of using a validated composite tool to 41 
measure SES, published studies only applied selected dimensions, such as income 42 
and education to represent SES, and hence may lead to biased conclusions 43 
(Banta-Green, Merrill, Doyle, Boudreau, & Calsyn, 2009; Joynt et al., 2013; McDonald 44 
et al., 2012; Parsells Kelly et al., 2008; Stover et al., 2006; Svendsen, Fredheim, 45 
Romundstad, Borchgrevink, & Skurtveit, 2014; Toblin, Mack, Perveen, & Paulozzi, 46 
2011). 47 
 48 
In the United Kingdom (UK), regional variation in health care provision has been 49 
identified in several diseases and regarded as an important health equity issue 50 
(Lawlor, Bedford, Taylor, & Ebrahim, 2003; Shah et al., 2016; Williams & Drinkwater, 51 
2009). However, research on the variation in opioid utilization and its association with 52 
SES remain lacking. Locally, a cross-sectional study conducted in 111 of the 192 53 
practices (780,000 registrants) in Leeds and Bradford found that higher number of 54 
opioid prescribing was associated with lower SES (Foy et al., 2016), but this 55 
association has not been investigated at the national level. Therefore, this study 56 
aimed to examine the association between SES and the number of prescription 57 
9 
opioids dispensed in England general practices using a validated composite indicator 58 
for SES. 59 
 60 
Methods 61 
Study design and data sources 62 
This cross-sectional study used publicly available aggregate-level statistics and 63 
datasets from multiple UK government sources. The most up-to-date information on 64 
SES (in 2015) was linked with opioid utilization and other population characteristics 65 
data by the identifier at practice level (Table 1). Practices in England which had opioid 66 
prescriptions dispensed in 2015 with an identifiable number of registrants and Index 67 
of Multiple Deprivation (IMD) scores were included as the basic unit for exploring 68 
regional variation in this study.  69 
 70 
In the UK, primary care practices are the gatekeepers for delivering healthcare in a 71 
locality with an average population size of 7139 people in 2015 (NHS Digital, 2016). 72 
Most people generally register with one general practice near their home (NHS 73 
Choices, 2016). Variation in registrants’ characteristics or disease history at a 74 
practice-level have been published or are available from Public Health England 75 
(Lawlor et al., 2003; Public Health England, 2016a; Shah et al., 2016; Williams & 76 
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Drinkwater, 2009).  77 
 78 
Monthly practice-level dispensing data from January to December 2015 were used to 79 
calculate opioid utilization (NHS Digital, 2015a). In England, the quantity of 80 
prescription medicines dispensed is collected monthly by the UK National Health 81 
Service (NHS) Digital and stratified by practices (NHS Digital, 2015a). Dispensing 82 
data of opioid preparations prescribed for pain relief (excluding those for opioid 83 
substitution therapy), including morphine, fentanyl, oxycodone, buprenorphine, 84 
hydromorphone, pethidine, tapentadol, tramadol, codeine, dihydrocodeine, 85 
dextropropoxyphene and meptazinol, were extracted for analysis based on the British 86 
National Formulary classification.  87 
 88 
IMD scores obtained from the Department of Communities and Local Government in 89 
2015 (Department for Communities and Local Government, 2015) were used to 90 
represent the SES of each practice. Within each practice, the number of female 91 
registrants and the number of registrants over 65 years were retrieved from NHS 92 
Digital (NHS Digital, 2015b). Other characteristics of registrants were identified from 93 
the Quality of Outcomes Framework (QOF) indicators in 2015 (NHS Digital, 2015c). 94 
Those aggregate-level data are publicly available and requires no ethical approval.  95 
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 96 
<Insert Table 1> 97 
 98 
Prescription opioid utilization 99 
‘Opioid utilization’ was measured using the total quantity of prescription opioids 100 
dispensed and expressed as the number of Defined Daily Doses (DDDs)/1000 101 
registrants/day for each practice. All opioids dispensed between January and 102 
December 2015 that could be assigned a DDD, according to the definitions from 103 
World Health Organization (World Health Organization, 2016), were extracted from 104 
the NHS Digital monthly practice-level dispensing data. The total amount of each 105 
opioid dispensed was calculated by multiplying the strength and quantity retrieved 106 
from the database. 107 
 108 
For each practice, the sum of the total quantity of each opioid in 2015 was divided by 109 
the DDD for each opioid. To derive the number of DDDs/1000 registrants/day of 110 
dispensed opioid, the number of DDDs for each opioid were summed, divided by the 111 
total number of registrants in the practice, multiplied by 1000, and divided by 365. 112 
 113 
From 2012, practices in England were grouped into Clinical Commissioning Groups 114 
12 
(CCGs) which are responsible for the planning and commissioning of healthcare 115 
services in a local area. In order to study geographical variation in opioid utilization 116 
across England, practices were grouped by CCG. The number of DDDs/1000 117 
registrants/day of dispensed opioid for each CCG was derived by dividing the total 118 
number of DDDs for each opioid by the number of registrants in the CCGs (Office for 119 
National Statistics, 2015b), multiplied by 1000, and divided by 365. 120 
 121 
Socioeconomic status 122 
To define the SES of each practice, an IMD score was assigned to each practice 123 
through the linkage of practice postcode and Lower-Layer Super Output Areas (LSOA) 124 
code, which was retrieved from the UK Office for National Statistics (ONS) (Office for 125 
National Statistics, 2015a). LSOA is the unit designed to improve the reporting of 126 
small area statistics, such as SES in England and Wales. The mean population size 127 
across the 32844 LSOAs was approximately 1500 residents (Office for National 128 
Statistics, 2011). 129 
 130 
The IMD is the official measure of SES in England. It is often used to quantify SES 131 
and to inform the implementation of health-related policy (Department for 132 
Communities and Local Government, 2015). IMD scores are calculated using seven 133 
13 
individually weighted domains, including income, employment, education, health, 134 
crime, barriers to housing and services and living environment. The IMD score ranges 135 
from 0 to 100, and a LSOA with higher IMD score indicates a lower SES area. In 136 
addition, each LSOA was ranked from the greatest to lowest IMD score, and the IMD 137 
rank was categorized into deciles. Therefore, a LSOA with lower IMD decile indicates 138 
a lower SES area (Department for Communities and Local Government, 2015). 139 
 140 
Characteristics of registrants 141 
Based on published literature, specific characteristics of registrants within practices 142 
were retrieved and measured to adjust for potential determinants of opioid utilization 143 
(Bauer, Hitchner, Harrison, Gerstenberger, & Steiger, 2016; Foy et al., 2016; 144 
Fredheim et al., 2014; Halbert, Davis, & Wee, 2016; Sullivan et al., 2008; Sullivan, 145 
Edlund, Zhang, Unutzer, & Wells, 2006).  146 
 147 
In this study, the proportion of current smokers, obesity registrants and diagnosed for 148 
cancer, depression and mental illness (such as schizophrenia, bipolar affective 149 
disorder and other psychoses) was directly extracted from 2015 QOF indicators. QOF 150 
indicators are pay-for-performance indicators introduced in 2004 as part of the 151 
general practice contract for better management of chronic diseases and major public 152 
14 
health concerns by remunerating general practices for achieving clinical targets (NHS 153 
Digital, 2015c), and hence the targets vary each year slightly. 154 
 155 
The proportion of female registrants and registrants aged over 65 years were 156 
calculated by dividing the number of female registrants and registrants aged over 65 157 
years by the total number of registrants within each practice (NHS Digital, 2015b).  158 
 159 
Data analysis 160 
Descriptive and regression analysis were applied to all practices in England to 161 
explore the association between SES and prescription opioid dispensed at the 162 
national level. In addition, subgroup analysis was conducted in practices from the top 163 
four primary urban areas, including London, Birmingham, Manchester and Newcastle 164 
to examine the consistency of the association at the regional level. The four primary 165 
urban areas represent different regions within England, and have diverse 166 
demographics, ethnicity, immigration, employment and welfare status (Centre for 167 
cities, 2011). According to the ONS 2011 census (Office for National Statistics, 2013), 168 
the estimated population size in the top four primary urban areas accounted for 30% 169 
of the total population in England, and the proportion of the population born outside 170 
the UK ranged from 7.3% to 34%. 171 
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 172 
Descriptive statistics were used to report median and interquartile range (IQR) of 173 
opioid utilization, IMD score and registrant characteristics across practices in England 174 
and the top four primary urban areas. Each CCG was categorized into a quartile 175 
based on opioid utilization and presented graphically to illustration the geographical 176 
distribution of opioid utilization.  177 
 178 
Simple linear regression was used to measure the correlation between decile in IMD 179 
domains, registrant characteristics, and opioid utilization for each practice. 180 
Characteristics of registrants included the proportion of females, registrants aged 181 
over 65 years, current smokers, obesity registrants and diagnosed for cancer, 182 
depression and mental illness.  183 
 184 
As healthcare policies and commissioning differ between CCGs, the association 185 
between opioid utilization (the dependent variable) and the independent variables, i.e. 186 
IMD deciles and characteristics of registrants in each practice, was further analyzed 187 
by random-intercept multilevel mixed-effects linear regression with restricted 188 
maximum likelihood estimation (Snijders, 2011). The full model included all variables 189 
and the regression results were presented as a coefficient and 95% confidence 190 
16 
interval (95% CI).  191 
 192 
As the cluster effect of CCG was identified by the likelihood-ratio test for all practices 193 
in England and practices in London, the random-intercept multilevel mixed-effects 194 
linear regression was applied to estimate the association between opioid utilization, 195 
IMD deciles and characteristics of registrants. It considered random effects and 196 
allowed different intercepts for practices within CCGs, and other variables to be 197 
included as fixed-effects. In contrast, as the likelihood-ratio test showed there was no 198 
cluster effect from CCGs for practices in Birmingham, Manchester and Newcastle, a 199 
multiple linear regression was applied. All analysis was performed using STATA 14 200 
(Stata-Corp, Texas, USA, 2015). 201 
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Results 202 
Analysis of practices at the national level 203 
Opioid utilization and registrants’ characteristics among practices 204 
Of the 7856 practices included from England, the median number of registrants was 205 
6565 (IQR: 3974, 9898), and median amount of dispensed opioid prescriptions was 206 
36.9 (IQR: 23.1, 52.5) DDD/1000 registrants/day. The median IMD score across the 207 
7856 practices in England was 22.4 (IQR: 12.4, 37.0) with a median decile of 4 (IQR: 208 
2, 7) (Table 2). 209 
 210 
<Insert Table 2> 211 
 212 
Geographical distribution of opioid utilization among CCGs 213 
The 7856 practices were grouped into 209 CCGs in England. The prescription opioids 214 
dispensed (DDD/1000 registrants/day) in each CCG ranged from 14.1 to 108.3, with 215 
the median of 42.7 (IQR: 32.9, 54.9). CCGs located in northern and eastern areas 216 
had higher opioid utilization and more likely to be ranked in the highest third and 217 
fourth quartiles of all CCGs. For the majority of CCGs located in London and 218 
surrounding areas, the number of prescription opioids dispensed was less than 30 219 
DDD/1000 registrants/day, and they were mostly ranked in the lowest quartile (Figure 220 
1).  221 
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 222 
<Insert Figure 1> 223 
 224 
Factors associated with opioid utilization 225 
The simple linear regression found that lower IMD decile (lower SES) were 226 
significantly associated with higher opioid utilization in practices across England. 227 
Similarly, for individual IMD domains including income, employment, education and 228 
skills, health and disability and crime, a significant negative association with opioid 229 
utilization was found. Barriers to housing and services and living environment were 230 
significantly positively associated with opioid utilization for practices in England. A 231 
significant positive association was found between opioid utilization and registrants’ 232 
demographics and QOF indicators (Table 3). 233 
 234 
<Insert Table 3> 235 
 236 
Association between opioid utilization and socioeconomic status 237 
For all practices in England, a significant cluster effect of CCGs was found (variance 238 
of the error: 94.2; 95%CI: 76.7, 115.8; p<0.0001). To every decrease in IMD decile 239 
(lower SES), there was a significant increase in opioid utilization of 1.0 (95%CI: 0.89, 240 
19 
1.2, P<0.001) DDD/1000 registrants/day after adjusting for registrants’ characteristics. 241 
In addition, opioid utilization also significantly increased with the increase in the 242 
proportion of registrants aged over 65 years, female gender, current smokers, obesity 243 
and depression. However, the proportion of registrants with mental health diseases 244 
was negatively associated with opioid utilization (Table 4). 245 
 246 
<Insert Table 4> 247 
 248 
Subgroup analysis of practices from the top four primary urban areas 249 
In the four primary urban areas, the median opioid utilization varied between 53.1 250 
(IQR: 36.8, 71.4), 48.9 (IQR: 38.8, 60.1), 35.3 (IQR: 23.1, 49.4) and 13.9 (IQR: 8.1, 251 
18.8) DDD/1000 registrants/day for practices in Manchester (n=204), Newcastle 252 
(n=175), Birmingham (n=326) and London (n=825), respectively. The lowest median 253 
IMD score was 25.9 (IOQ: 13.5, 45.2) in Newcastle followed by London (28.6, IQR: 254 
18.7, 37.5), Manchester (37.0, IQR: 24.8, 51.5) and Birmingham (38.5, IQR: 21.6, 255 
52.6) (Table 2).  256 
 257 
For practices in Manchester, Birmingham and London, opioid utilization significantly 258 
increased by 2.7 (95%CI: 1.2, 4.1), 0.82 (95%CI: 0.08, 1.6) and 0.60 (95%CI: 0.31, 259 
20 
0.90) DDD/1000 registrants/day for each decrease in IMD decile. However, IMD 260 
decile was not significantly associated with opioid utilization in Newcastle. Although 261 
the proportion of registrants aged over 65 years and current smokers were 262 
significantly associated with opioid utilization in the four primary urban areas, an 263 
inconsistent association between opioid utilization, female gender and other QOF 264 
indicators was found between practices in the four cities (Table 4) (Appendix 1).  265 
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Discussion 266 
Main findings 267 
This study found regional variation in opioid utilization and registrant characteristics 268 
among practices across England and within the four primary urban areas. The 269 
geographical distribution of opioid utilization also varied across CCGs in England. 270 
There was a substantial variation in prescription opioids dispensed among practices 271 
from Northern and Eastern England to Southern England which mirrors general 272 
geographical health inequalities between those from deprived and affluent areas. The 273 
highest opioid utilization was 108.3 DDD/1000 registrants/day, equating to 274 
approximately 10% of the registrants in the CCGs using 1 DDD of prescription opioid 275 
on any given day. 276 
 277 
Aggregate population data demonstrated that practices located in lower SES areas 278 
had higher opioid utilization. For every decrease in IMD decile, one more opioid DDD 279 
was prescribed and dispensed per 1000 registrants/day. In the subgroup analysis, 280 
which considered the variation in demographics, ethnicity and welfare across 281 
geographical areas in England, this association was also observed in the top four 282 
primary urban areas ranging from 0.6 to 2.7 DDD/1000 registrants/day. In addition to 283 
IMD, older age, female gender, current smoking, obesity and depression were 284 
22 
associated with higher opioid utilization.  285 
 286 
Consistent evidence of association between socioeconomic status and opioid 287 
utilization  288 
The association between SES and regional variation of opioid utilization involves a 289 
complex interaction between social determinants, patients’ medicine-taking behavior, 290 
pain conditions and physicians’ prescribing behavior (Figure 2). For example, greater 291 
physical labor and unemployment led to higher rates of opioid utilization in Australia 292 
(Degenhardt et al., 2016) and unemployment was associated with problematic opioid 293 
use and dependence (Campbell et al., 2015). In Norway, patients with higher 294 
education level were found to be less likely to become persistent opioid users 295 
(Svendsen et al., 2014) as they tended to accept a non-opioid analgesic as an 296 
effective medication (Gebauer, Salas, & Scherrer, 2017).  297 
 298 
<Insert Figure 2> 299 
 300 
This study used the IMD score to summarise SES and these results were consistent 301 
with published cross-sectional studies comparing opioid utilization between counties 302 
in the US (McDonald et al., 2012) and Statistical Local Areas in Australia (Degenhardt 303 
23 
et al., 2016) which also found that higher opioid utilization was associated with lower 304 
SES which were measured by selected dimensions. Furthermore, this study identified 305 
a significant association between higher opioid utilization and registrants’ 306 
characteristics, i.e. current smokers, obesity and depression that have not been found 307 
in published studies applied aggregate-level data (Degenhardt et al., 2016; McDonald 308 
et al., 2012).  309 
 310 
Regarding the population demographics, this study found that female gender was 311 
associated with higher opioid utilization. This result is similar to a study exploring 312 
variation in opioid prescribing and its associated factors among patients with 313 
fibromyalgia (Painter et al., 2013). However, this is in contract to the study conducted 314 
by Degenhardt et al. (2016) in Australia which showed that male gender was related 315 
to higher opioid utilization (Degenhardt et al., 2016). The reasons for this discrepancy 316 
may be due to the inclusion of methadone in the opioid utilization calculation; it has 317 
been reported that more than 65% of patients receiving methadone therapy in 318 
Australia between 2007 to 2016 were male (Australian Institute of Health and Welfare, 319 
2017).  320 
 321 
24 
Need for evidence-based guidance on opioid prescribing 322 
In the UK, the use of prescription opioids is required to comply with the strict 323 
controlled drug regulations. Therefore, the total amount of opioids dispensed in each 324 
region or CCG can also be regarded as an indicator for pain management needs in 325 
primary care. The 2011 Health Survey for England suggested that the lower 326 
household income is related to higher prevalence of chronic pain conditions 327 
(Department of Health, 2012). This finding was consistent with studies conducted in 328 
Germany whereby lower neighborhood SES was related to inferior physical health 329 
(Voigtlander, Berger, & Razum, 2010), and a US study which indicated an association 330 
between neighborhood SES and receipt of opioid among patients with back pain 331 
(Gebauer et al., 2017).  332 
 333 
Long-term opioid use for chronic non-cancer pain (CNCP) is not supported by current 334 
clinical guidance (Hauser et al., 2014; Manchikanti et al., 2012; Public Health England, 335 
2016b), and there is no consensus on duration or dose recommendation for chronic 336 
opioid use. In addition, the availability and accessibility of opioids may be influenced 337 
by prescribers’ clinical training (Linge-Dahl et al., 2015) and health care practitioners’ 338 
clinical knowledge, and regional opioid prescribing guidance have been suggested to 339 
be associated with regional variation in opioid utilization (Reames et al., 2014). In this 340 
25 
study, the significant CCG-related cluster effect implies that the local opioid 341 
prescribing policy among CCGs could also contribute to the variation in opioid 342 
prescriptions.  343 
 344 
To reduce variations in population health outcomes, studies about regional variation 345 
in health care delivery in the UK identified areas which may require further policy 346 
investigations (Hollingworth et al., 2015). To fully understand the influence of chronic 347 
opioid utilization for CNCP on regional variation in opioid utilization and to inform 348 
future policy intervention, national studies exploring opioid utilization in patients with 349 
CNCP across geographical regions are needed. Moreover, to clarify the relationship 350 
between SES and opioid utilization, further longitudinal studies using 351 
individual-patient data from practices in England are needed.  352 
 353 
Strengths and limitations 354 
This nationwide study showed regional variation in opioid utilization among practices 355 
and an association between opioid utilization and SES using aggregated level 356 
population data from UK government sources which included all practices and had 357 
better generalizability. An official and standardized deprivation score was applied to 358 
summarise SES, and hence the association was not biased by particular dimensions 359 
26 
in SES, a limitation which has affected prior studies. 360 
 361 
For unmeasured similarity among practices within CCGs, the cluster effects of CCGs 362 
were also considered in the analysis. Furthermore, comparing to previous nationwide 363 
studies conducted in other countries (Degenhardt et al., 2016; McDonald et al., 2012), 364 
this study used QOF indicator data which is a reliable data source for identifying and 365 
adjusting for specific patient characteristics and registrant comorbidities as it was 366 
introduced in primary cares to remunerate general practices for achieving clinical 367 
targets.  368 
 369 
The following limitations of this study should be acknowledged. As this study used 370 
statistics and datasets collected at an aggregate-level rather than individual level, the 371 
variation in demographic characteristics and comorbidities among registrants within 372 
practices cannot be measured. It is possible that the estimated opioid utilization was 373 
consumed by only a few users who were prescribed and dispensed large quantities of 374 
the drug. Furthermore, as the dataset only included dispensing opioid prescriptions at 375 
an aggregate-level, the use of illicit opioids, such as heroin use, at an individual 376 
patient level was not included in the scope of this study. Moreover, due to data 377 
restriction and the implementation of CCGs in 2012, this study used only the most 378 
27 
up-to-date information from one calendar year (2015). Ideally, further studies should 379 
acquire information from multiple years, including the upcoming calendar years, to 380 
validate the consistency of the association between SES and prescription opioids 381 
dispensed at the population level.  382 
 383 
In addition, it is possible that the interaction between SES and the prevalence of 384 
chronic pain conditions may have influenced the observed regional variation of 385 
prescription opioids dispensed. However, the common CNCP pain conditions, such 386 
as low back pain and arthritis, were not targeted as part of the 2015 QOF indicators 387 
(NHS Digital, 2015c), hence were not included in the regression analysis. These 388 
unmeasured CNCP pain conditions might explain the non-significant association 389 
between SES and opioid utilization in Newcastle.  390 
 391 
In conclusion, there was marked variation in opioid utilization and characteristics of 392 
registrants among practices in England. Higher opioid utilization was associated with 393 
lower SES when adjusted demographic characteristics. Individual-level longitudinal 394 
studies are needed to explore the association between SES, CNCP and opioid 395 
utilization between geographical regions in the UK. 396 
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Figure 
 
 
 
 
 
 
Figure 1. Opioid utilization among Clinical Commissioning Groups in 
England 
 
 First (Lowest ): 14.1- 32.9 (DDD/1000 registrants/day) 
 Second: 32.9 – 42.7 (DDD/1000 registrants/day) 
 Third: 42.7 – 54.9 (DDD/1000 registrants/day) 
 Fourth (Upper): 54.9-108.3 (DDD/1000 registrants/day) 
Note: DDD: Defined Daily Dose 
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(Note) IMD: Index of Multiple Deprivation, *: Significant factors identified in this study. 
Figure 2. Factors related to the regional variation of prescription opioids utilization
Prescription 
opioid 
utilization 
Chronic 
non-cancer 
pain 
(Painter, 2013) 
Demographics 
(McDonald, 2012) 
Characteristics 
Socioeconomic 
status 
Lower household income 
(Department of Health, 2012) 
Physical labor (Degenhardt, 2016) 
Unemployment (Degenhardt, 2016; Campbell, 2015) 
Education level (Svnden, 2014) 
Accessing to healthcare (McDonald, 2012) 
 
Insurance coverage (Zerzan, 2006) 
 
Prescribing guidance (Reams, 2014) 
 
Prescribers’ knowledge (Reams, 2014) 
 
 
* Age ≥ 65 years 
*Female 
* Smoker 
* Obesity 
* Depression 
* Mental health diseases 
 
* IMD deciles, income, employment, education and skill, health and disability, crime, barriers to 
housing and services and living environment 
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Tables 
Table 1. Summary of aggregated-level statistics and datasets used in this study 
Data source Dataset Countries and time Information retrieved from datasets Outcome measure used is this study 
NHS Digital 
(NHS Digital, 
2015a)
 
Monthly practice-level 
dispensing data  
England, January to 
December 2015 
Monthly quantity of dispensed opioid 
preparations for each practice 
DDD/1000 inhabitants/day at practice 
and CCG level 
NHS Digital 
(NHS Digital, 
2015b)
 
Numbers of patients 
registered at a GP practice 
England, January to 
December 2015 
For each practice: 
Number of registrants 
Number of females  
Number of patients aged more than 65 years 
DDD/1000 inhabitants/day at practice 
level 
Proportion of female gender 
Proportion of registrants aged more 
than 65 years 
NHS Digital 
(NHS Digital, 
2015c)
 
Quality and Outcomes 
Framework - 2014-15 
England, 2014 Proportion of registrants with particular 
characteristics in each practice 
Proportion of registrants with 
particular characteristics 
Department of 
Communities and Local 
Government 
(Department for 
Communities and Local Government, 
2015)
 
All ranks, deciles and scores 
for the indices of deprivation, 
and population denominators 
England, 2015 Score and decile of IMD and individual 
domains for each practice 
Score and decile of IMD and 
individual domains 
Office for National 
Statistics 
(Office for National 
Statistics, 2015b)
 
Mid-2014 population 
estimates for CCGs in 
England by single year of age 
and sex 
England, 2014 Number of registrants in each CCG DDD/1000 inhabitants/day at CCG 
level 
(Note) NHS: National Health Service, DDD: Defined Daily Dose, IMD: Index of Multiple Deprivation, CCG: Clinical Commissioning Groups, GP: general practitioner 
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Table 2. Opioid utilization and characteristics of registrants in practices in England and the four cities 
 
All practices 
(n=7,856) 
Practices in London 
(n=825) 
Practices in 
Birmingham 
(n=326) 
Practices in 
Manchester 
(n=204) 
Practices in 
Newcastle 
(n=175) 
Number of registrants 6565 (3974, 9898) 6229 (3827, 9123) 5054 (3054, 8871) 5631 (3557, 8403) 6095 (4295, 9153) 
Opioid utilization (DDD/1000 registrants/day) 36.9 (23.1, 52.5) 13.9 (8.1, 18.8) 35.3 (23.1, 49.4) 53.1 (36.8, 71.4) 48.9 (38.8, 60.1) 
Socioeconomic status       
IMD score  22.4 (12.4, 37.0) 28.6 (18.7, 37.5) 38.5 (21.6, 52.6) 37.0 (24.8, 51.5) 25.9 (13.5, 45.2) 
IMD decile  4 (2, 7) 3 (2, 5) 2 (1, 4) 2 (1, 4) 4 (1, 7) 
Income decile  4 (2, 7) 3 (2, 5) 2 (1, 5) 2 (1, 4) 4 (1, 6) 
Employment decile  4 (2, 7) 4 (3, 6) 2 (1, 5) 2 (1, 4) 3 (1, 6) 
Education and skills decile  5 (3, 7) 7 (5, 9) 3 (1, 5) 3 (2, 6) 4 (2, 8) 
Health and disability decile  4 (2, 7) 5 (3, 7) 3 (2, 5) 1 (1, 3) 2 (1, 4) 
Crime decile  4 (2, 7) 2 (1, 4) 3 (2, 5) 3 (1, 5) 6(4, 8) 
Barriers to housing and services decile  7 (4, 9) 2 (1, 4) 3 (1, 6) 6 (4, 8.5) 7 (5, 9) 
Living environment decile  4 (2, 7) 2 (1, 3) 3 (1, 4) 3 (2, 5) 8 (6, 9) 
Proportion of registrant demographics and Quality of Outcomes Framework indicators 
Age over 65 years 17.1 (12.1, 21.2) 9.2 (6.8, 12.2) 14.4 (9.4, 18.4) 12.6 (9.1, 16.7) 18.9 (15.4, 21.7) 
Female gender 50.3 (49.0, 51.2 ) 49.9 (47.9, 51.6) 49.8 (47.5, 50.8) 49.6 (47.6, 50.7) 50.6 (49.0, 51.3) 
Current smokers 18.5 (14.6, 22.9) 19.7 (16.2, 22.5) 19.2 (15.4, 23.6) 22.7 (18.8, 28.5) 19.4 (14.5, 23.1) 
Obesity 9.0 (6.8, 11.6) 6.9 (4.9, 9.6) 9.4 (7.3, 11.6) 9.3 (7.3, 11.9) 11.8 (9.1, 13.9) 
Depression 6.9 (4.9, 9.1) 5.4 (3.7, 7.1) 6.4 (4.4, 9.1) 8.1 (5.4, 10.8) 7.4 (5.1, 9.7) 
Mental health diseases 0.83 (0.64, 1.1) 1.2 (0.89, 1.5) 0.92 (0.70, 1.2) 1.0 (0.75, 1.3) 0.85 (0.69, 1.1) 
Cancer 2.2 (1.6, 2.8) 1.4 (1.0, 1.8) 1.9 (1.1, 2.5) 1.8 (1.2, 2.3) 2.5 (2.1, 2.9) 
(Note) IMD: Index of Multiple Deprivation, DDD: Defined Daily Dose; all statistics are presented in median and interquartile range 
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Table 3. Association between registrant characteristics and opioid utilization in univariate analysis 
 Practices in England Practices in London Practices in Birmingham Practices in Manchester Practices in Newcastle 
Socioeconomic status 
IMD decile  -2.2* (-2.4, -2.1)  -0.87* (-1.1, -0.61)  0.05 (-0.76, 0.53)  -3.0* (-4.6, -1.4)  -2.3* (-3.1, -1.5)  
Income decile  -2.3* (-2.5, -2.1)  -0.91* (-1.1, -0.68)  -0.13 (-0.94, 0.69)  -3.7* (-5.2, -2.3)  -2.6* (-3.4, -1.8)  
Employment decile  -3.1* (-3.3, -2.9)  -0.77* (-0.99, -0.55)  -0.18 (-0.98, 0.63)  -4.9* (-6.3, -3.4)  -2.8* (-3.6,-2.1)  
Education and skills decile  -3.2* (-3.4, -3.0)  -0.84* (-1.1, -0.59)  --0.50 (-1.2, 0.22)  -4.0* (-5.3, -2.7)  -2.2* (-3.0, -1.5)  
Health and disability decile  -3.4* (-3.6, -3.3)  -0.96* (-1.2, -0.73)  -0.40 (-1.3, 0.51)  -4.0* (-6.5, -1.5)  -3.1* (-4.1, -2.0)  
Crime decile  -0.47*(-0.65, -0.30)  -0.69* (-1.0, -0.36)  -0.41 (-1.4, 0.59)  -0.26 (-1.8, 1.3)  -1.8* (-2.8, -0.86)  
Barriers to housing and services decile  2.5* (2.3, 2.6)  -0.44* (-0.73, -0.15)  1.5* (0.78, 2.2)  1.5* (0.17, 2.8)  -0.08 (-1.1, 0.95)  
Living environment decile  0.62* (0.44, 0.81)  0.77* (0.33, 1.2)  1.3* (0.43, 2.2)  2.8* (0.89, 4.7)  0.70 (-0.36, 1.75)  
Proportion of registrants’ demographics 
Age over 65 years 1.1* (1.0, 1.1) 0.28* (0.19, 0.37) 1.3* (1.0, 1.6) 2.3* (1.6, 2.9) 0.36 (-0.11, 0.82) 
Female 0.66* (0.49, 0.84) -0.05 (-0.18, 0.08)  2.1* (1.6, 2.7)  2.2* (0.84, 3.5)  0.37 (-0.83, 1.57)  
Proportion of Quality of Outcomes Framework indicators 
Current smokers  1.3* (1.2, 1.4)  0.49* (0.38, 0.59)  1.6* (1.3, 1.8)  2.1* (1.7, 2.6)  1.6* (1.3, 1.4)  
Obesity 2.6* (2.5, 2.7)  0.69* (0.53, 0.86)  1.3* (0.72, 1.9)  2.1* (1.2, 3.1)  2.3* (1.6, 3.0)  
Depression  2.2* (2.0, 2.3)  0.61* (0.39, 0.83)  2.3* (1.8, 2.8)  2.2* (1.4, 3.0)  1.4* (0.69, 2.1)  
Mental health diseases 1.7* (0.88, 2.6)  2.1* (1.5, 2.7)  -0.19 (-4.9, 4.6)  5.9 (-2.4, 14.2)  16.6* (8.4, 24.7)  
Cancer  7.1* (6.5, 7.6)  2.5* (1.8, 3.3)  8.6* (6.5, 10.7)  13.3* (8.8, 17.8)  1.8 (-1.9, 5.6)  
(Note) * p<0.05, IMD: Index of Multiple Deprivation, all statistics are presented in coefficient and 95% confidence interval 
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Table 4. Association between socioeconomic status, registrant characteristics and opioid utilization in the multi-level 
regression analysis 
 Practices in England Practices in London Practices in Birmingham Practices in Manchester Practices in Newcastle 
Socioeconomic status 
IMD decile  -1.0* (-1.2, -0.89)  -0.60* (-0.90, -0.31)  -0.82* (-1.6, -0.08)  -2.7* (-4.1, -1.2) -0.16 (-0.98, 0.65)  
Proportion of registrant demographics 
Age over 65 years  1.2* (1.1, 1.3)  0.69* (0.50, 0.87)  1.8* (1.3, 2.3)  2.6* (1.7, 3.4)  1.2* (0.53, 1.9)  
Female 0.84* (0.71, 0.96)  0.39* (0.24, 0.54)  1.7* (1.1, 2.3)  0.76 (-0.27, 1.8)  1.9* (0.88, 2.8)  
Proportion of Quality of Outcomes Framework indicators 
Current smokers  1.3* (1.2, 1.4)  0.49* (0.35, 0.63)   1.4* (1.1, 1.7)  1.9* (1.4, 2.4)  2.3* (1.7, 2.8)  
Obesity 0.36* (0.27, 0.46) 0.04 (-0.14, 0.21) 0.38 (-0.03, 0.79)  -0.26 (-1.0, 0.50)  0.23 (-0.43, 0.89)  
Depression  0.43* (0.33, 0.53)  0.21 (-0.01, 0.42)  0.69* (0.23, 1.1)  0.64 (-0.03, 1.3)  0.35 (-0.23, 0.92)  
Mental health diseases -2.7* (-3.4, -2.1)  0.71 (-0.06, 1.5) -1.6 (-5.1, 1.9)  -6.4 (-12.9, 0.13)  -5.3 (-12.9, 2.3)  
Cancer  -0.006 (-0.67, 0.66) 0.07 (-1.2, 1.4)  -3.9* (-7.5, -0.39)  0.34 (-5.5, 6.1)  -0.48 (-5.6, 4.6)  
Random effects at the CCG level 
The variance of the error
+
  94.2* (76.7, 115.8) 8.5* (4.2, 17.1) NA NA NA 
(Note) * p<0.05, IMD: Index of Multiple Deprivation, CCG: Clinical Commissioning Groups, NA: not applicable, all statistics are presented in coefficient and 95% confidence 
interval, + presented in variance and 95% confidence interval 
40 
Supplementary material 
Appendix 1. Association between opioid utilization, socioeconomic status and 
characteristics of registrants in the four primary urban areas 
The median opioid utilization for practices in Manchester, Newcastle, Birmingham 
and London were 53.1 (IQR: 36.8, 71.4), 48.9 (IQR: 38.8, 60.1), 35.3 (IQR: 23.1, 49.4) 
and 13.9 (IQR: 8.1, 18.8) DDD/1000 registrants/day, and the lowest median IMD 
score was found in Newcastle (25.9 IOQ: 13.5, 45.2) followed by London (28.6, IQR: 
18.7, 37.5), Manchester (37.0, IQR: 24.8, 51.5) and Birmingham (38.5, IQR: 21.6, 
52.6).  
 
In the simple liner regression, a negative association between IMD decile and opioid 
utilization was found in London, Manchester and Newcastle but not in Birmingham. A 
significant negative association between individual IMD domains, such as income, 
employment, education and skills and health and disability and opioid utilization was 
found in London, Manchester and Newcastle but not in Birmingham. In addition, a 
significant negative association was found between crime and opioid utilization for 
practices across London and Newcastle but not in Birmingham or Manchester.  
 
Barriers to housing and services and living environment were significantly positively 
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associated with opioid utilization in practices in Manchester and Birmingham. 
However, lower barriers to housing and services decile and higher living environment 
decile were significantly associated with higher opioid utilization for practices in 
London. Regarding registrants’ demographics and QOF indicators, only current 
smokers, obesity and depression were consistently associated with opioid utilization 
in the practices in the four major cities. 
 
After adjusting for registrants’ characteristics, SES was significantly associated with 
opioid utilization in Manchester, Birmingham and London. However, IMD decile was 
not significantly associated with opioid utilization in Newcastle despite a significant 
association found in univariate analysis. 
 
In addition, across the cities, opioid utilization significantly increased as the proportion 
of females increased, except in Manchester. A positive association between opioid 
utilization and proportion of depression registrants was only found in practices in 
Birmingham. Furthermore, a negative association between cancer and opioid 
utilization was only found for practices in Birmingham.
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Birmingham. A significant negative association between individual IMD 
domains, such as income, employment, education and skills and health and 
disability and opioid utilization was found in London, Manchester and 
Newcastle but not in Birmingham. In addition, a significant negative 
association was found between crime and opioid utilization for practices 
across London and Newcastle but not in Birmingham or Manchester.  
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positively associated with opioid utilization in practices in Manchester and 
Birmingham. However, lower barriers to housing and services decile and 
higher living environment decile were significantly associated with higher 
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consistently associated with opioid utilization in the practices in the four major 
cities. 
 
After adjusting for registrants’ characteristics, SES was significantly 
associated with opioid utilization in Manchester, Birmingham and London. 
However, IMD decile was not significantly associated with opioid utilization in 
Newcastle despite a significant association found in univariate analysis. 
 
In addition, across the cities, opioid utilization significantly increased as the 
proportion of females increased, except in Manchester. A positive association 
between opioid utilization and proportion of depression registrants was only 
found in practices in Birmingham. Furthermore, a negative association 
between cancer and opioid utilization was only found for practices in 
Birmingham. 
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